bumetanide has been researched along with Hypertension in 51 studies
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In CKD stage 4-5 KDIGO without renal replacement therapy, bumetanide in combination with chlorthalidone is more effective in treating volume overload and hypertension than bumetanide with placebo." | 9.51 | Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial. ( Cabrera-Barron, R; Chida-Romero, JA; Dehesa-López, E; Madero, M; Martin-Alemañy, G; Perez-Navarro, LM; Solis-Jimenez, F; Valdez-Ortiz, R, 2022) |
| "1 Twelve patients with mild hypertension were treated with bumetanide for a six-month period." | 9.04 | Lack of effect of bumetanide on body potassium content in hypertension. ( Bewsher, PD; Murchison, LE, 1975) |
| "The effect of bumetanide on absolute and fractional sodium excretion, creatinine clearance, and plasma renin activity (PRA) was studied in eight patients with essential hypertension before and after indomethacin." | 7.66 | Influence of indomethacin on the natriuretic and renin-stimulating effect of bumetanide in essential hypertension. ( Arzilli, F; Magagna, A; Pedrinelli, R; Salvetti, A; Sassano, P, 1980) |
| "In CKD stage 4-5 KDIGO without renal replacement therapy, bumetanide in combination with chlorthalidone is more effective in treating volume overload and hypertension than bumetanide with placebo." | 5.51 | Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial. ( Cabrera-Barron, R; Chida-Romero, JA; Dehesa-López, E; Madero, M; Martin-Alemañy, G; Perez-Navarro, LM; Solis-Jimenez, F; Valdez-Ortiz, R, 2022) |
| "The behaviour of active (AR) and inactive (IR) renin was studied in 48 hypertensive patients (37 with uncomplicated essential hypertension and 11 with reno-vascular hypertension) treated with indomethacin alone or with AR stimulating (bumetanide, tienilic acid, captopril) and inhibiting (atenolol) drugs before and after indomethacin addition." | 5.05 | Effects of prostaglandins inhibition on changes in active and inactive renin induced by antihypertensive drugs. ( Arzilli, F; Pedrinelli, R; Salvetti, A; Sassano, P; Turini, F, 1982) |
| "1 Twelve patients with mild hypertension were treated with bumetanide for a six-month period." | 5.04 | Lack of effect of bumetanide on body potassium content in hypertension. ( Bewsher, PD; Murchison, LE, 1975) |
| "The Na(+)-K(+)-2Cl(-) cotransporter 1 (NKCC1) is one of several transporters that have been implicated for development of hypertension since NKCC1 activity is elevated in hypertensive aorta and vascular contractions are inhibited by bumetanide, an inhibitor of NKCC1." | 3.76 | Promoter hypomethylation upregulates Na+-K+-2Cl- cotransporter 1 in spontaneously hypertensive rats. ( Baek, I; Cho, HM; Hong, SH; Kim, IK; Lee, DY; Lee, HA; Seok, YM; Yang, E, 2010) |
| " Pump activity appears higher and furosemide or bumetanide sensitive Na+ efflux lower in SHR compared to WKY suggesting a similar abnormality in SHR genetic hypertension as in human hypertension." | 3.66 | Furosemide and bumetanide-sensitive Na+ fluxes in erythrocytes from genetically hypertensive rats (SHR). ( De Mendonca, M; Garay, R; Grichois, ML; Herubel, A; Knorr, A; Meyer, P; Toumi, K, 1981) |
| "The effect of bumetanide on absolute and fractional sodium excretion, creatinine clearance, and plasma renin activity (PRA) was studied in eight patients with essential hypertension before and after indomethacin." | 3.66 | Influence of indomethacin on the natriuretic and renin-stimulating effect of bumetanide in essential hypertension. ( Arzilli, F; Magagna, A; Pedrinelli, R; Salvetti, A; Sassano, P, 1980) |
| "Forty patients with congestive heart failure or hypertensive heart disease were given long-term maintenance treatment with a combined bumetanide/slow-release potassium supplement preparation ('Burinex K')." | 3.65 | Patient tolerance of long-term diuretic/potassium supplement therapy. ( Singh, BB; Watt, DA, 1976) |
| "The inhibition of dose-response curves by bumetanide, an inhibitor of NKCC1, as well as the expression of Nkcc1 mRNA and protein was comparable between 5-week-old SHR and age-matched WKY, but greater in 18-week-old SHR than in age-matched WKY." | 1.37 | Expression of Na+-K+ -2Cl- cotransporter 1 is epigenetically regulated during postnatal development of hypertension. ( Cho, HM; Han, HS; Kim, HY; Kim, IK; Lee, HA, 2011) |
| " administration, the pharmacokinetic and pharmacodynamic parameters of bumetanide did not vary significantly between SHRs and the control Wistar rats." | 1.29 | Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt induced hypertensive rats. ( Han, KS; Kim, ND; Lee, MG; Lee, SH, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (47.06) | 18.7374 |
| 1990's | 16 (31.37) | 18.2507 |
| 2000's | 7 (13.73) | 29.6817 |
| 2010's | 3 (5.88) | 24.3611 |
| 2020's | 1 (1.96) | 2.80 |
| Authors | Studies |
|---|---|
| Solis-Jimenez, F | 1 |
| Perez-Navarro, LM | 1 |
| Cabrera-Barron, R | 1 |
| Chida-Romero, JA | 1 |
| Martin-Alemañy, G | 1 |
| Dehesa-López, E | 1 |
| Madero, M | 1 |
| Valdez-Ortiz, R | 1 |
| Lee, HA | 3 |
| Baek, I | 1 |
| Seok, YM | 2 |
| Yang, E | 1 |
| Cho, HM | 3 |
| Lee, DY | 2 |
| Hong, SH | 1 |
| Kim, IK | 3 |
| Kim, HY | 2 |
| Han, HS | 1 |
| Vokurková, M | 1 |
| Dobesová, Z | 3 |
| Kunes, J | 3 |
| Zicha, J | 5 |
| Jiang, G | 1 |
| Akar, F | 1 |
| Cobbs, SL | 1 |
| Lomashvilli, K | 1 |
| Lakkis, R | 1 |
| Gordon, FJ | 1 |
| Sutliff, RL | 1 |
| O'Neill, WC | 1 |
| Bell, AM | 1 |
| Nolen, JD | 1 |
| Knudson, CM | 1 |
| Raife, TJ | 1 |
| De Mendonca, M | 3 |
| Grichois, ML | 2 |
| Toumi, K | 1 |
| Herubel, A | 1 |
| Knorr, A | 3 |
| Garay, R | 2 |
| Meyer, P | 2 |
| Bönner, G | 1 |
| Unger, T | 1 |
| Rascher, W | 1 |
| Speck, G | 1 |
| Ganten, D | 1 |
| Gross, F | 1 |
| Salvetti, A | 2 |
| Pedrinelli, R | 2 |
| Sassano, P | 2 |
| Arzilli, F | 2 |
| Turini, F | 1 |
| Ben-Ishay, D | 1 |
| Garay, RP | 5 |
| Kokubu, T | 1 |
| Hiwada, K | 1 |
| Shishido, M | 1 |
| Murakami, E | 1 |
| Hashimoto, H | 1 |
| Wester, PO | 1 |
| Magagna, A | 1 |
| Luque Otero, M | 2 |
| Fernández Pinilla, C | 2 |
| Bórquez, M | 1 |
| Fernández Cruz, A | 4 |
| Humair, L | 1 |
| McMurchie, EJ | 1 |
| Burnard, SL | 1 |
| Patten, GS | 1 |
| King, RA | 1 |
| Howe, PR | 1 |
| Head, RJ | 1 |
| Bin Talib, HK | 1 |
| Han, KS | 1 |
| Lee, SH | 1 |
| Lee, MG | 1 |
| Kim, ND | 1 |
| Davis, JP | 2 |
| Chipperfield, AR | 2 |
| Harper, AA | 2 |
| Parés, I | 1 |
| de la Sierra, A | 2 |
| Coca, A | 2 |
| Lluch, MM | 1 |
| Urbano-Márquez, A | 1 |
| Vincent, M | 1 |
| van der Heijden, M | 1 |
| Donders, SH | 1 |
| Cleophas, TJ | 1 |
| Niemeyer, MG | 1 |
| van der Meulen, J | 1 |
| Bernink, PJ | 1 |
| de Planque, BA | 1 |
| van der Wall, EE | 1 |
| Alvarez-Guerra, M | 2 |
| Nazaret, C | 2 |
| Michea, L | 1 |
| Irribarra, V | 1 |
| Goecke, IA | 1 |
| Marusic, ET | 1 |
| Yan, Y | 1 |
| Dempsey, RJ | 1 |
| Sun, D | 1 |
| Godfraind, T | 1 |
| de la Fuente, A | 1 |
| Nielsen, K | 1 |
| Arrigoni-Martelli, E | 1 |
| Vichi, FL | 1 |
| de Oliveira, AC | 1 |
| Fariña, FR | 1 |
| Bernardes F, J | 1 |
| Martins, JD | 1 |
| Mazotti, L | 1 |
| Dahlberg, A | 1 |
| Fagerberg, SE | 1 |
| Murchison, LE | 1 |
| Bewsher, PD | 1 |
| Singh, BB | 1 |
| Watt, DA | 1 |
| Yokomatsu, M | 1 |
| Fujito, K | 1 |
| Numahata, H | 1 |
| Koide, H | 1 |
| Ferrari, P | 3 |
| Torielli, L | 2 |
| Salardi, S | 2 |
| Rizzo, A | 1 |
| Bianchi, G | 3 |
| Talib, HK | 2 |
| Klír, P | 1 |
| Kren, V | 1 |
| Pravenec, M | 1 |
| Masereel, B | 1 |
| Ferrandi, M | 1 |
| Pirotte, B | 1 |
| Schynts, M | 1 |
| Parenti, P | 1 |
| Delarge, J | 1 |
| Cirillo, M | 1 |
| Salvati, P | 1 |
| Ferrario, RG | 1 |
| Garthoff, B | 1 |
| Morich, F | 1 |
| Kazda, S | 1 |
| Aguilera, MT | 1 |
| Urbano Márquez, A | 1 |
| Senn, N | 1 |
| Wilcox, CS | 1 |
| Loon, NR | 1 |
| Ameer, B | 1 |
| Limacher, MC | 1 |
| Ng, LL | 1 |
| Harker, M | 1 |
| Abel, ED | 1 |
| Tokushige, A | 1 |
| Kino, M | 1 |
| Tamura, H | 1 |
| Hopp, L | 1 |
| Searle, BM | 1 |
| Aviv, A | 1 |
| Darlington, LG | 1 |
| Delva, P | 1 |
| De Gasperi, M | 1 |
| Degan, M | 1 |
| Covi, G | 1 |
| Lechi, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial[NCT03923933] | Phase 2 | 34 participants (Actual) | Interventional | 2019-06-18 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -3.4 |
| Treatment Grup | -13.5 |
Decrease in extracellular water measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.15 |
| Treatment Grup | 2.55 |
Decrease in extracellular water / total body water ratio measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of ECW/TBW (Mean) |
|---|---|
| Placebo | -0.24 |
| Treatment Grup | -2.92 |
decrease in blood pressure compared wit baseline measure (mmhg) (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -5.4 |
| Treatment Grup | -18.1 |
(NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | mmHg (Mean) |
|---|---|
| Placebo | -10 |
| Treatment Grup | -26.1 |
Increase in the fractional excretion of sodium compared with the baseline measure (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | percentage of sodium excreted (Mean) |
|---|---|
| Placebo | -0.348 |
| Treatment Grup | 0.598 |
Measured by bioelectrical impedance analysis, compared to the initial measurement (NCT03923933)
Timeframe: Change from Basal to day 28
| Intervention | litres (Mean) |
|---|---|
| Placebo | -0.075 |
| Treatment Grup | -4.36 |
1 review available for bumetanide and Hypertension
| Article | Year |
|---|---|
NKCC2: a drug target in hypertension.
Topics: Animals; Bumetanide; Diuretics; Humans; Hypertension; Rats; Sodium Potassium Chloride Symporter Inhi | 2002 |
7 trials available for bumetanide and Hypertension
| Article | Year |
|---|---|
Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4-5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial.
Topics: Aged; Bumetanide; Chlorthalidone; Humans; Hypertension; Middle Aged; Renal Insufficiency, Chronic; R | 2022 |
Effects of prostaglandins inhibition on changes in active and inactive renin induced by antihypertensive drugs.
Topics: Adult; Atenolol; Bumetanide; Captopril; Cold Temperature; Diuretics; Enzyme Precursors; Female; Glyc | 1982 |
Urinary zinc excretion during treatment with different diuretics.
Topics: Adult; Aged; Bendroflumethiazide; Bumetanide; Chlorthalidone; Clinical Trials as Topic; Diuretics; F | 1980 |
A randomized, placebo-controlled study of loop diuretics in patients with essential hypertension: the bumetanide and furosemide on lipid profile (BUFUL) clinical study report.
Topics: Adult; Aged; Antihypertensive Agents; Bumetanide; Cross-Over Studies; Diuretics; Double-Blind Method | 1998 |
[Antihypertensive effects of bumetanide treatment].
Topics: Aged; Bumetanide; Clinical Trials as Topic; Diuretics; Drug Evaluation; Female; Humans; Hypertension | 1976 |
Lack of effect of bumetanide on body potassium content in hypertension.
Topics: Adult; Body Composition; Bumetanide; Diuretics; Female; Humans; Hypertension; Liver; Male; Middle Ag | 1975 |
Renal and hemodynamic responses to bumetanide in hypertension: effects of nitrendipine.
Topics: Bumetanide; Diuretics; Drug Interactions; Female; Hemodynamics; Humans; Hypertension; Male; Middle A | 1989 |
43 other studies available for bumetanide and Hypertension
| Article | Year |
|---|---|
Promoter hypomethylation upregulates Na+-K+-2Cl- cotransporter 1 in spontaneously hypertensive rats.
Topics: Adrenergic alpha-Agonists; Animals; Aorta; Base Sequence; Bumetanide; DNA Methylation; Epigenesis, G | 2010 |
Expression of Na+-K+ -2Cl- cotransporter 1 is epigenetically regulated during postnatal development of hypertension.
Topics: Animals; Aorta; Bumetanide; DNA (Cytosine-5-)-Methyltransferases; Epigenomics; Gene Expression Regul | 2011 |
Upregulation of the Na(+)-K(+)-2Cl(-) cotransporter 1 via histone modification in the aortas of angiotensin II-induced hypertensive rats.
Topics: Angiotensin II; Animals; Aorta; Blood Pressure; Blotting, Western; Bumetanide; Chromatin Immunopreci | 2012 |
Membrane ion transport in erythrocytes of salt hypertensive Dahl rats and their F2 hybrids: the importance of cholesterol.
Topics: Animals; Biological Transport; Blood Pressure; Bumetanide; Cholesterol; Diuretics; Enzyme Inhibitors | 2003 |
Blood pressure regulates the activity and function of the Na-K-2Cl cotransporter in vascular smooth muscle.
Topics: Animals; Aortic Coarctation; Blood Pressure; Bumetanide; Cardiomegaly; Diuretics; Enzyme Inhibitors; | 2004 |
Severe citrate toxicity complicating volunteer apheresis platelet donation.
Topics: Adult; Blood Donors; Bumetanide; Citric Acid; Female; Humans; Hypertension; Hypocalcemia; Plateletph | 2007 |
Furosemide and bumetanide-sensitive Na+ fluxes in erythrocytes from genetically hypertensive rats (SHR).
Topics: 4-Chloromercuribenzenesulfonate; Animals; Biological Transport, Active; Bumetanide; Erythrocytes; Fu | 1981 |
The renal kallikrein-kinin system in spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Blood Pressure; Body Weight; Bumetanide; Erythrocyte Indices; Hypertension; | 1984 |
Erythrocytic sodium ion transport systems in primary and secondary hypertension of the rat.
Topics: Animals; Bumetanide; Erythrocytes; Female; Furosemide; Hypertension; Hypertension, Renal; Hypertensi | 1982 |
Reduced responses of renin release to three different stimuli in essential hypertensive patients of stage II (WHO stage classification).
Topics: Adult; Blood Pressure; Bumetanide; Depression, Chemical; Diet, Sodium-Restricted; Female; Humans; Hy | 1980 |
Influence of indomethacin on the natriuretic and renin-stimulating effect of bumetanide in essential hypertension.
Topics: Adult; Blood Pressure; Bumetanide; Creatinine; Diuretics; Drug Interactions; Female; Heart Rate; Hum | 1980 |
[The effect of therapeutic diuresis in carbohydrate tolerance in essential hypertension (author's transl)].
Topics: Adult; Blood Glucose; Bumetanide; Carbohydrate Metabolism; Diuretics; Female; Humans; Hypertension; | 1981 |
[Bumetanide in renal insufficiency].
Topics: Aged; Bumetanide; Diuretics; Female; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; L | 1982 |
Depressed cheek cell sodium transport in human hypertension.
Topics: Amiloride; Biological Transport; Body Mass Index; Bumetanide; Carrier Proteins; Cheek; Epithelium; F | 1994 |
Red cell ouabain-resistant Na+ and K+ transport in Wistar, Brown Norway and spontaneously hypertensive rats.
Topics: Animals; Bumetanide; Cell Membrane Permeability; Drug Resistance; Erythrocytes; Hypertension; Ion Tr | 1993 |
Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt induced hypertensive rats.
Topics: Administration, Oral; Animals; Body Weight; Bumetanide; Desoxycorticosterone; Dose-Response Relation | 1993 |
Accumulation of intracellular chloride by (Na-K-Cl) co-transport in rat arterial smooth muscle is enhanced in deoxycorticosterone acetate (DOCA)/salt hypertension.
Topics: Animals; Bumetanide; Chlorides; Desoxycorticosterone; Femoral Artery; Hypertension; Ion Transport; M | 1993 |
Detection of a circulating inhibitor of the Na(+)-K(+)-Cl(-) cotransport system in plasma and urine after high salt intake.
Topics: Adult; Aged; Blood; Blood Physiological Phenomena; Bumetanide; Carrier Proteins; Diet, Sodium-Restri | 1995 |
Relationship of red blood cell ion transport alterations and serum lipid abnormalities in Lyon genetically hypertensive rats.
Topics: Animals; Blood Pressure; Bumetanide; Cell Membrane Permeability; Chlorides; Cholesterol; Erythrocyte | 1997 |
Activation of two inward chloride transport systems in rat femoral arterial smooth muscle in deoxycorticosterone acetate/salt hypertension.
Topics: Acetazolamide; Animals; Anions; Bumetanide; Chloride Channels; Desoxycorticosterone; Diuretics; Hype | 1997 |
The erythrocyte Na,K,Cl cotransporter and its circulating inhibitor in Dahl salt-sensitive rats.
Topics: Animals; Bumetanide; Carrier Proteins; Chlorides; Diuretics; Erythrocyte Membrane; Humans; Hypertens | 1998 |
Reduced Na-K pump but increased Na-K-2Cl cotransporter in aorta of streptozotocin-induced diabetic rat.
Topics: Animals; Aorta; Biological Transport; Blotting, Western; Bumetanide; Carrier Proteins; Diabetes Mell | 2001 |
Na+-K+-Cl- cotransporter in rat focal cerebral ischemia.
Topics: Animals; Astrocytes; Autoradiography; Brain Chemistry; Brain Edema; Bumetanide; Carrier Proteins; Ce | 2001 |
Renal Na-K-Cl cotransporter NKCC2 in Dahl salt-sensitive rats.
Topics: Animals; Bumetanide; Chlorides; Cytosol; Diuretics; Hypertension; In Vitro Techniques; Ion Transport | 2002 |
[Treatment of arterial hypertension with bumetanide and clonidine].
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Bumetanide; Clonidine; Diuretics; Drug Therapy, C | 1979 |
Effects on rat urinary kallikrein excretion of bumetanide, bendroflumethiazide and hydralazine.
Topics: Administration, Oral; Animals; Bendroflumethiazide; Bumetanide; Diuretics; Hydralazine; Hypertension | 1977 |
[Bumetanide in the treatment of congestive heart failure and arterial hypertension].
Topics: Body Weight; Bumetanide; Diuresis; Diuretics; Drug Therapy, Combination; Heart Failure; Humans; Hype | 1978 |
Patient tolerance of long-term diuretic/potassium supplement therapy.
Topics: Adult; Aged; Bumetanide; Diuretics; Drug Combinations; Female; Heart Diseases; Heart Failure; Humans | 1976 |
Erythrocyte sodium ion transport system in DOC-salt, Goldblatt, and spontaneously hypertensive rats.
Topics: Animals; Bumetanide; Erythrocytes; Hypertension; Hypertension, Renovascular; Ion Transport; Male; Ou | 1992 |
Na+/K+/Cl- cotransport in resealed ghosts from erythrocytes of the Milan hypertensive rats.
Topics: Animals; Bumetanide; Cell Membrane Permeability; Chlorides; Erythrocyte Membrane; Hypertension; In V | 1992 |
Association of red blood cell sodium leak with blood pressure in recombinant inbred strains.
Topics: Analysis of Variance; Animals; Biological Transport; Blood Pressure; Bumetanide; Erythrocytes; Furos | 1992 |
Na+,2Cl-,K+ cotransport system as a marker of antihypertensive activity of new torasemide derivatives.
Topics: Animals; Blood Pressure; Bumetanide; Chlorine; Diuretics; Erythrocytes; Hypertension; In Vitro Techn | 1992 |
Red cell sodium in DOCA-salt hypertension: a Brattleboro study.
Topics: Animals; Biological Transport, Active; Blood Pressure; Bumetanide; Desoxycorticosterone; Erythrocyte | 1992 |
Sodium transport kinetics in erythrocytes and inside-out vesicles from Milan rats.
Topics: Animals; Bumetanide; Cytoplasm; Erythrocyte Membrane; Erythrocytes; Hypertension; Male; Rats; Rats, | 1991 |
Diuretic effect of bumetanide in isolated perfused kidneys of Milan hypertensive rats.
Topics: Animals; Bumetanide; Diuresis; Diuretics; Hypertension; Kidney; Male; Perfusion; Potassium; Rats; Re | 1990 |
Chronic treatment with nifedipine prevents development of hypertension and abnormal red cell Na+ transport in Dahl-S-rats.
Topics: Animals; Bumetanide; Erythrocyte Membrane; Erythrocytes; Female; Hypertension; In Vitro Techniques; | 1985 |
Abnormal erythrocyte sodium leak in a subset of essential hypertensive patients.
Topics: Adult; Aged; Biological Transport; Bumetanide; Erythrocytes; Female; Humans; Hypertension; Ion Chann | 1989 |
Regulation of Na+ and K+ contents in rat thymocytes.
Topics: Animals; Biological Transport; Blood Coagulation Factors; Bumetanide; Dinoprostone; Hypertension; Is | 1989 |
Mechanisms of leucocyte sodium influx in essential hypertension.
Topics: Amiloride; Bumetanide; Female; Humans; Hypertension; Leukocytes; Male; Sodium | 1988 |
Bumetanide-sensitive sodium-22 transport in vascular smooth muscle cell of the spontaneously hypertensive rat.
Topics: Animals; Biological Transport, Active; Bumetanide; Calcium; Diuretics; Erythrocytes; Hypertension; K | 1986 |
Study to compare the relative hyperuricaemic effects of frusemide and bumetanide.
Topics: Aged; Bumetanide; Diuretics; Edema; Female; Furosemide; Heart Failure; Humans; Hypertension; Male; M | 1986 |
Kinetics of bumetanide-sensitive Na+-K+ co-transport in erythrocytes of essential hypertensive patients.
Topics: Adolescent; Adult; Biological Transport; Bumetanide; Cell Membrane Permeability; Diuretics; Erythroc | 1985 |
Na+ leak in erythrocytes from essential hypertensive patients.
Topics: Adult; Aged; Biological Transport; Bumetanide; Calcium; Cell Membrane Permeability; Erythrocytes; Fe | 1985 |